Publicações

Adverse Events (Aes) as Potential Predictive Factors of Activity in Patients with Advanced Hepatocellular Carcinoma (Hcc) Treated with Atezolizumab plus Bevacizumab (Ab)

AuthID
P-00Z-QQW

Author(s)

Persano, M

Rimini, M

Tada, T

Suda, G

Shimose, S

Kudo, M

Yoo, C

Cheon, J

Finkelmeier, F

Lim, HY

Presa, J

Masi, G

Bergamo, F

Iavarone, MA

Cabibbo, G

Foschi, FG

Piscaglia, F

Cascinu, S

Scartozzi, M

Gardini, AC

Document Type

Abstract

Year published

2023

Published

in ANNALS OF ONCOLOGY, ISSN: 0923-7534

Volume: 34, Pages: S1535-S1535 (1)

Conference

Annual Meeting of the European-Society-For-Medical-Oncology (Esmo), Date: DEC 01-03, 2023, Location: SINGAPORE

Indexing

Wos^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1016/j.annonc.2023.10.289

Wos: WOS:001122475400157

Source Identifiers

ISSN: 0923-7534

Export Publication Metadata

Lista Marked

Adicionar à lista Marked

Info

At this moment we don't have any links to full text documens.

Adverse Events (Aes) as Potential Predictive Factors of Activity in Patients with Advanced Hepatocellular Carcinoma (Hcc) Treated with Atezolizumab plus Bevacizumab (Ab)

Useful Links

Get Help

Autenticação Federada (Click on the image)

Adverse Events (Aes) as Potential Predictive Factors of Activity in Patients with Advanced Hepatocellular Carcinoma (Hcc) Treated with Atezolizumab plus Bevacizumab (Ab)

Useful Links

Get Help